DongBang Medical

At a glance

DongBang Medical filed 36 disclosures in the last 12 months, including 6 insider. The most recent key filing was on Feb 23.

Revenue for 2025 was ₩114B, up 8% on 2024. Operating margin was 15% against 14.3% a year earlier. Debt was 49% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩65.3B and operating profit of ₩12.4B.

The 2025 annual report lists 305 employees with an average tenure of 4.8 years and average pay of ₩42M, #2038 of 2,191 listed companies by average pay. Its 6 directors and auditors were paid ₩108M each on average. It paid no cash dividend for 2025. 김근식 and related parties held 48.57% at year end.

From the 2025 annual report

Staff: 305 (143 men, 162 women), of whom 24 on fixed-term contracts. Total pay for the year: ₩12.8B. Directors and auditors: 6, paid ₩648M in total.

No cash dividend was paid for 2025.

Largest shareholder

김근식 holds 48.01%; with 2 related parties the group holds 48.57% of common shares at year end (from 48.58% at the start of the year).

Auditor: 대성회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary